XML 64 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Installment
$ / shares
shares
Mar. 19, 2021
USD ($)
Jan. 31, 2022
USD ($)
Sep. 30, 2020
Jan. 31, 2016
USD ($)
shares
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Installment
$ / shares
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Installment
shares
Oct. 27, 2020
shares
Feb. 28, 2018
USD ($)
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Net change to contingent consideration             $ 1,622,000 $ 818,000      
Put option liability               3,400,000      
Warrants, expires period Feb. 23, 2028           Feb. 23, 2028        
Estimated air value of warrants issued $ 300,000           $ 300,000        
Increase in value of the warrant liability               1,252,000      
IPO                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Warrant, exercise price | $ / shares $ 4.46           $ 4.46        
Warrant issued to purchase shares | shares 103,326           103,326     103,326  
Series F Preferred Stock                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Contingent value rights shares | shares         3,999            
Contingent value rights         $ 500,000            
Contingent value rights percentage         0.00375%            
Net proceeds percentage of cash payment to the CVR holders         15.00%            
Series F Preferred Stock | AVEO Oncology                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Percentage of development and regulatory costs exercised using opt-out right       50.00%              
2018 Notes                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Repayments of Debt   $ 25,900,000                  
Estimated air value of warrants issued                     $ 300,000
2018 Notes | Series G Preferred Stock                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Warrant issued to purchase shares | shares 613,333           613,333       613,333
Warrant, exercise price | $ / shares $ 0.75           $ 0.75        
Second Amendment                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Repayments of Debt $ 20,000,000                    
Milestone payment $ 4,600,000                    
Second Amendment | Subsequent Event                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Milestone payment     $ 4,600,000                
Operating Expense                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Net change to contingent consideration               $ 800,000      
Operating Expense | Loss                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Net change to contingent consideration             $ 1,600,000        
Interest Expense                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Net change to contingent consideration             $ 2,200        
Integrated Diagnostics, Inc                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business acquisition description             requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month        
Business acquisition contingent consideration gross margin target           $ 2,000,000.0 $ 2,000,000.0   $ 2,000,000.0    
Business acquisition contingent consideration gross margin target period                 7 years    
Integrated Diagnostics, Inc | Common Stock                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business acquisition description             If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.        
Contingent consideration shares | shares                 2,520,108    
Contingent consideration number of installments | Installment 6           6   8    
Contingent consideration arrangements, common shares, redemption amount             $ 4,600,000   $ 37,000,000.0    
Repayments of Debt             9,300,000        
Business combination contingent consideration final payment             $ 37,000,000.0        
Integrated Diagnostics, Inc | Common Stock | Repurchase                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Contingent consideration number of installments | Installment                 2    
Contingent consideration cash payment                 $ 37,000,000.0    
Minimum                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range             11.00%        
Maximum                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range             13.50%